| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥16.3B | ¥16.1B | +1.7% |
| Operating Income | ¥2.0B | ¥1.5B | +33.0% |
| Ordinary Income | ¥2.3B | ¥1.8B | +29.9% |
| Net Income | ¥1.6B | ¥1.1B | +45.3% |
| ROE | 4.1% | 2.8% | - |
FY2025 Q3 cumulative results show revenue of 1.63 billion yen (YoY +1.7%), operating income of 201 million yen (YoY +33.0%), ordinary income of 229 million yen (YoY +29.9%), and net income of 159 million yen (YoY +45.3%). Operating margin expanded to 12.3% from 9.5% in the prior year period, while net margin reached 9.7%. The company demonstrates strong profitability improvement despite modest revenue growth, with operating income rising significantly faster than sales. Total assets decreased to 4.87 billion yen from 5.03 billion yen, while equity increased slightly to 3.89 billion yen from 3.86 billion yen, maintaining a solid equity ratio of 79.8%. The profit surge was driven by margin expansion rather than volume growth, with segment-level improvements in X-ray residual stress measurement equipment offsetting weakness in healthcare equipment.
Revenue increased 1.7% to 1.63 billion yen, with modest top-line expansion across the business portfolio. Segment-level analysis reveals X-ray residual stress measurement equipment as the primary growth driver, posting revenue of 665 million yen (up 45.8% YoY) and representing 40.7% of total sales. Healthcare equipment segment generated 325 million yen (down 37.2% YoY), showing significant contraction that partially offset gains elsewhere. Optical application and special equipment segment contributed 642 million yen (up 1.6% YoY), maintaining stable performance. The divergence in segment performance reflects varying demand dynamics across end markets, with industrial measurement equipment benefiting from capital investment cycles while healthcare-related demand faced headwinds.
Operating income surged 33.0% to 201 million yen despite limited revenue growth, indicating substantial operating leverage and margin expansion. Segment profit analysis shows X-ray equipment profit of 264 million yen (up 66.4% YoY) with margin expansion to 39.7% from 34.8%, while healthcare equipment posted a loss of 7 million yen versus 32 million yen profit in the prior year. Optical and special equipment delivered profit of 174 million yen (down 9.5% YoY) with margin compression to 27.1% from 30.4%. Corporate expenses of 233 million yen remained relatively stable. The profit improvement was primarily driven by the X-ray segment's scale benefits and operational efficiency gains.
Ordinary income of 229 million yen exceeded operating income by 28 million yen, indicating net non-operating income contribution of approximately 1.7% of revenue. Net income reached 159 million yen, representing 69.4% conversion from ordinary income, with the effective tax burden absorbing approximately 30% of pre-tax earnings. No material extraordinary items or impairments were identified in the reporting period.
The performance pattern represents revenue up/profit up, with profit growth significantly outpacing revenue expansion through margin improvement and operational efficiency gains concentrated in the core X-ray measurement equipment segment.
X-ray residual stress measurement equipment segment generated revenue of 665 million yen (up 45.8% YoY) and operating profit of 264 million yen (up 66.4% YoY), achieving a segment margin of 39.7% compared to 34.8% in the prior year. This segment represents the core business with 40.7% revenue share and serves as the primary profit engine, demonstrating strong pricing power and operational leverage. Healthcare equipment segment posted revenue of 325 million yen (down 37.2% YoY) with an operating loss of 7 million yen versus 32 million yen profit in the prior year, reflecting margin pressure from volume decline and fixed cost absorption challenges. Optical application and special equipment segment contributed revenue of 642 million yen (up 1.6% YoY) and operating profit of 174 million yen (down 9.5% YoY), with segment margin of 27.1% compared to 30.4% previously. The margin differential between segments is material, with X-ray equipment demonstrating superior profitability at 39.7% versus 27.1% for optical equipment and negative margins in healthcare. The divergent segment performance highlights concentration risk in X-ray equipment profitability while healthcare represents a turnaround opportunity requiring operational improvements.
[Profitability] ROE of 4.1% remains below the industry median of 5.0%, while operating margin of 12.3% exceeds the industry median of 8.3% and net profit margin of 9.7% substantially outperforms the industry median of 6.3%. ROA of 3.3% aligns with the industry median of 3.3%. The profitability metrics demonstrate strong operational efficiency at the EBIT and net income levels, though return on equity lags due to low financial leverage utilization. [Cash Quality] Cash and equivalents of 1.87 billion yen provide coverage of 3.4 times against short-term liabilities of 550 million yen, indicating robust liquidity. Working capital metrics show concerning trends with receivables turnover of 146 days (DSO) significantly exceeding the industry median of 83 days, and inventory turnover of 354 days (DIO) far above the industry median of 109 days. The cash conversion cycle of 484 days substantially exceeds typical manufacturing sector benchmarks of 108 days, indicating capital tied up in working capital. [Investment Efficiency] Asset turnover of 0.335 substantially underperforms the industry median of 0.58, reflecting inefficient asset utilization driven by elevated working capital balances. ROIC of 4.1% remains below the industry median of 5.0%, consistent with the capital efficiency challenges. [Financial Health] Equity ratio of 79.8% substantially exceeds the industry median of 63.8%, indicating conservative capital structure with minimal leverage. Current ratio of 626.8% far exceeds the industry median of 284%, demonstrating exceptional short-term liquidity. Debt-to-equity ratio of 0.25 reflects minimal financial leverage, with net debt to EBITDA significantly negative at approximately negative 6.8 compared to industry median of negative 1.11, indicating net cash position.
Cash and deposits increased to 1.87 billion yen from prior levels, with the company maintaining a substantial net cash position supporting financial flexibility. Working capital movements show concerning trends with accounts receivable and inventory balances expanding significantly, absorbing operating cash generation. The receivables balance suggests extended collection cycles or revenue concentration in slow-paying customers, while inventory accumulation of 2.20 billion yen with work-in-process representing 61.4% of total inventory indicates production process bottlenecks or extended manufacturing lead times. The cash conversion cycle of 484 days represents material deterioration from sector norms, suggesting substantial capital trapped in the operating cycle. Despite working capital headwinds, the company maintains cash coverage of 3.4 times against short-term obligations, indicating adequate near-term liquidity. The balance sheet shows no material short-term debt, with total liabilities of 990 million yen primarily comprising operating payables. The combination of strong cash reserves and minimal debt provides financial stability, though working capital efficiency deterioration constrains effective cash generation from operations.
Ordinary income of 229 million yen versus operating income of 201 million yen shows non-operating net contribution of approximately 28 million yen, representing 1.7% of revenue. This comprises primarily financial income and other non-operating gains as components of the net non-operating contribution. The modest non-operating contribution suggests earnings are predominantly driven by core operations rather than financial engineering or one-time gains. The absence of material extraordinary items or impairments indicates recurring earnings quality. The relationship between operating and ordinary income shows stable non-operating contribution without significant volatility. Working capital metrics raise concerns about earnings quality from a cash realization perspective, with the 484-day cash conversion cycle indicating earnings generation substantially precedes cash collection. The elevated work-in-process inventory ratio of 61.4% suggests revenue recognition may be occurring on partially completed projects, requiring monitoring of percentage-of-completion accounting assumptions. While profitability metrics show strong improvement, the disconnect between profit growth and working capital deterioration warrants scrutiny of earnings sustainability and cash backing.
Full-year guidance projects revenue of 2.65 billion yen, operating income of 350 million yen, ordinary income of 343 million yen, and net income of 270 million yen. Current Q3 cumulative results show progress rates of 61.6% for revenue, 57.7% for operating income, 66.8% for ordinary income, and 58.9% for net income against full-year targets. Considering Q3 represents 75% of the fiscal year, revenue and operating income progress rates indicate below-standard achievement, suggesting either significant Q4 weighting in the business model or potential shortfall risk against guidance. The company projects full-year revenue growth of 6.6% and operating income growth of 4.1% compared to prior year, with ordinary income declining 3.0%. The modest operating income growth forecast versus current Q3 performance (operating income up 33.0% YoY cumulative) implies expectation of margin normalization or cost increases in Q4. The guidance assumes continued segment-level performance with potential moderation from current run rates. Annual dividend of 80 yen per share is incorporated in full-year assumptions based on forecast data.
Annual dividend of 110 yen per share for the fiscal year-end is disclosed in the period, with interim dividend of zero. The full-year payout represents 96.4% of net income based on current period earnings of 159 million yen annualized, indicating an elevated payout ratio. However, full-year guidance projects net income of 270 million yen with dividend per share of 80 yen according to forecast data, which would represent a more sustainable payout ratio of 40.5% if achieved. The divergence between period-end announced dividend of 110 yen and forecast dividend of 80 yen suggests either special dividend consideration or alignment to policy targets. No share buyback activity is disclosed in the reporting period. The company's substantial cash reserves of 1.87 billion yen and net cash position provide capacity to support dividends, though the elevated calculated payout ratio based on current period earnings warrants monitoring of dividend sustainability relative to cash generation. Total return ratio calculation is not applicable as only dividend information is available without buyback data.
Working capital management deterioration poses the most critical risk, with cash conversion cycle of 484 days substantially exceeding industry norms and tying up approximately 1.3 times annual revenue in operating assets. Accounts receivable of 146 days outstanding and inventory of 354 days turnover indicate either customer credit quality issues, production inefficiency, or demand forecasting misalignment. The work-in-process concentration of 61.4% suggests manufacturing bottlenecks or project delivery delays that could impair cash realization. Quantifiable impact includes opportunity cost of capital trapped in working capital estimated at 40-50 million yen annually assuming 3% cost of capital. Segment concentration risk is evident with X-ray residual stress measurement equipment contributing 264 million yen of 430 million yen total segment profit (61.4% of segment-level profitability), creating vulnerability to demand cycles in industrial capital equipment markets. Healthcare equipment segment losses of 7 million yen represent a turnaround challenge requiring operational restructuring. Dividend sustainability risk emerges from the 96.4% calculated payout ratio based on period earnings, though mitigated by substantial cash reserves and conservative capital structure. If working capital trends continue without remediation, free cash flow generation may become insufficient to support current dividend levels without depleting cash reserves.
[Industry Position] (Reference - Proprietary Analysis)
Profitability metrics demonstrate mixed performance versus manufacturing sector peers. Operating margin of 12.3% exceeds industry median of 8.3%, ranking in the upper quartile and indicating superior operational efficiency. Net profit margin of 9.7% substantially outperforms industry median of 6.3%, reflecting strong bottom-line conversion. However, ROE of 4.1% lags industry median of 5.0% due to minimal leverage utilization despite strong profitability, with equity ratio of 79.8% far exceeding industry median of 63.8%. ROA of 3.3% aligns with industry median of 3.3%, while ROIC of 4.1% slightly underperforms industry median of 5.0%.
Efficiency metrics reveal significant underperformance. Asset turnover of 0.335 substantially trails industry median of 0.58, placing the company in the bottom quartile for asset utilization efficiency. Working capital metrics show material deterioration with receivables turnover of 146 days versus industry median of 83 days, inventory turnover of 354 days versus industry median of 109 days, and total operating working capital cycle of 484 days versus industry median of 108 days. These metrics indicate capital efficiency substantially below peer standards.
Financial health indicators show conservative positioning. Current ratio of 626.8% far exceeds industry median of 284%, indicating excessive liquidity relative to operational needs. Net debt to EBITDA of approximately negative 6.8 versus industry median of negative 1.11 reflects substantial net cash position beyond typical sector standards. The minimal leverage profile provides financial stability but constrains ROE optimization.
Growth metrics align with sector trends, with revenue growth of 1.7% slightly below industry median of 2.7% but within interquartile range. EPS growth performance relative to peers requires consideration of the unique profit margin expansion dynamics.
※ Industry: Manufacturing (98 companies), Comparison: FY2025 Q3, Source: Proprietary analysis
Margin expansion driving profit growth represents the primary positive characteristic, with operating margin improving to 12.3% from 9.5% and operating income growth of 33.0% substantially exceeding revenue growth of 1.7%. The X-ray residual stress measurement equipment segment demonstrates strong competitive positioning with 39.7% segment margin and 45.8% revenue growth, indicating market share gains or favorable end-market conditions. The profitability improvement trend is observable across recent periods with operating margin of 12.3% in current period establishing new performance levels. Working capital deterioration constitutes the most significant concern observable from earnings data, with cash conversion cycle of 484 days and inventory turnover of 354 days indicating structural inefficiency in capital deployment. The working capital metrics substantially exceed manufacturing sector norms and represent material deviation from historical company performance, suggesting operational challenges in order-to-cash cycle management or demand planning. The earnings quality consideration emerges from the disconnect between strong profit growth and working capital absorption, with work-in-process inventory representing 61.4% of total inventory indicating potential revenue recognition timing issues or production bottlenecks.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.